118 related articles for article (PubMed ID: 9864428)
1. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
[TBL] [Abstract][Full Text] [Related]
2. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
[TBL] [Abstract][Full Text] [Related]
3. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
[TBL] [Abstract][Full Text] [Related]
5. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
6. Telomerase enzyme activity as a diagnostic tool to distinguish effusions of malignant and benign origin.
Spangler EA; Rogers KS; Thomas JS; Pustejovsky D; Boyd SL; Shippen DE
J Vet Intern Med; 2000; 14(2):146-50. PubMed ID: 10772485
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in pleural effusions: diagnostic significance.
Yang CT; Lee MH; Lan RS; Chen JK
J Clin Oncol; 1998 Feb; 16(2):567-73. PubMed ID: 9469342
[TBL] [Abstract][Full Text] [Related]
8. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
Zendehrokh N; Dejmek A
Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.
Magyarosy E; Martin WJ; Chu EW; Martin SE
Pathol Oncol Res; 1999; 5(1):32-5. PubMed ID: 10079375
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
Nagel H; Schlott T; Schulz GM; Droese M
Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic implications of telomerase activity in pleural effusions.
Dikmen G; Dikmen E; Kara M; Sahin E; Doğan P; Ozdemir N
Eur Respir J; 2003 Sep; 22(3):422-6. PubMed ID: 14516130
[TBL] [Abstract][Full Text] [Related]
12. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
Adell E; Dejmek A
Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
[TBL] [Abstract][Full Text] [Related]
14. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
Nieh S; Chen SF; Fu E; Jan CI; Lee WH
Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
[TBL] [Abstract][Full Text] [Related]
16. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.
Engelhardt M; Albanell J; Drullinsky P; Han W; Guillem J; Scher HI; Reuter V; Moore MA
Clin Cancer Res; 1997 Oct; 3(10):1849-57. PubMed ID: 9815573
[TBL] [Abstract][Full Text] [Related]
17. Role of DNA flow cytometry and immunocytochemical analysis in diagnosis of malignant effusions.
Kundu R; Handa U; Mohan H
Diagn Cytopathol; 2012 Oct; 40(10):887-92. PubMed ID: 21485027
[TBL] [Abstract][Full Text] [Related]
18. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
Zendehrokh N; Rehnberg J; Dejmek A
Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
[TBL] [Abstract][Full Text] [Related]
19. [The diagnostic value of telomerase activity in differentiating benign and malignant ascitic fluid].
Yang YL; Ma ZB; Xu HY
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):745-7. PubMed ID: 16255881
[TBL] [Abstract][Full Text] [Related]
20. Telomerase activity and hTERT mRNA expression in body fluids.
Yamamoto Y; Hirakawa E
Diagn Cytopathol; 2005 Mar; 32(3):167-70. PubMed ID: 15690332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
